Most Recent
Novartis patent for oral form of top-selling MS drug obvious, IP Australia says
Intellectual Property 2019-05-13 12:31 pm By Miklos Bolza

A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Juno Pharmaceuticals settles trade mark dispute with Juno Therapeutics
Intellectual Property 2019-01-25 3:42 pm By Miklos Bolza

Juno Pharmaceuticals has resolved its appeal of an IP Australia ruling that allowed Seattle-based Juno Therapeutics to extend protection of its namesake trade mark into Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?